Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-01
2011-03-01
Desai, Rita J (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S112000
Reexamination Certificate
active
07897611
ABSTRACT:
Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia), are treated by administering a compound of Formulas 1 or 2, as described herein. The compounds of Formulas 1 and 2 are also useful for treating pain, and treating drug addiction, nicotine addiction, and/or obesity. The compounds can exist as individual stereoisomers, racemic mixtures, diastereomers and the like.
REFERENCES:
patent: 4922901 (1990-05-01), Brooks
patent: 4965074 (1990-10-01), Leeson
patent: 5187166 (1993-02-01), Kikuchi
patent: 5210076 (1993-05-01), Berliner
patent: 5212188 (1993-05-01), Caldwell
patent: 5227391 (1993-07-01), Caldwell
patent: 5242935 (1993-09-01), Lippiello
patent: 5583140 (1996-12-01), Bencherif
patent: 5597919 (1997-01-01), Dull
patent: 5604231 (1997-02-01), Smith
patent: 5616716 (1997-04-01), Dull
patent: 5663356 (1997-09-01), Ruecroft
patent: 5672601 (1997-09-01), Cignarella
patent: 5852041 (1998-12-01), Cosford
patent: 5853696 (1998-12-01), Elmaleh
patent: 5861423 (1999-01-01), Caldwell
patent: 5952339 (1999-09-01), Bencherif
patent: 5969144 (1999-10-01), London
patent: 6310043 (2001-10-01), Bundle
patent: 6638925 (2003-10-01), Czollner
patent: 7402592 (2008-07-01), Breining et al.
patent: 2001/0056084 (2001-12-01), Allgeier
patent: 2002/0016371 (2002-02-01), Shytle
patent: 2005/0282823 (2005-12-01), Breining et al.
patent: 0 239 309 (1987-09-01), None
patent: 0 297 858 (1989-01-01), None
patent: 0 588 917 (1994-03-01), None
patent: 0 978 280 (2000-02-01), None
patent: 2 295 387 (1996-05-01), None
patent: WO 94/08992 (1994-04-01), None
patent: WO 96/30372 (1996-10-01), None
patent: WO 96/31475 (1996-10-01), None
patent: WO 96/36637 (1996-11-01), None
patent: WO 97/30998 (1997-08-01), None
patent: WO 98/25619 (1998-06-01), None
patent: WO 99/03859 (1999-01-01), None
patent: WO 99/21834 (1999-05-01), None
patent: WO 99/62505 (1999-12-01), None
patent: WO 99/65876 (1999-12-01), None
patent: WO 00/23424 (2000-04-01), None
patent: WO 01 /36417 (2001-05-01), None
patent: WO 02/15662 (2002-02-01), None
patent: WO 02/16355 (2002-02-01), None
patent: WO 02/16356 (2002-02-01), None
patent: WO 02/16357 (2002-02-01), None
patent: WO 02/16358 (2002-02-01), None
patent: WO 02/17358 (2002-02-01), None
patent: WO 2004/016604 (2004-02-01), None
patent: WO 2005/037832 (2005-04-01), None
Damaj et. al. “The antinociceptive effects of alpha-7 nicotinic agonists in an acute pain model” Neuropharmacology 39 (2000) 2785-2791.
Decker et. al. “Therapeutic Potential of Neuronal Nicotinic Acetylcholine Receptor Agonists as Novel Analgesics” Biochemical Pharmacology, vol. 58, pp. 917-923, 1999.
Adler, et al., “Normalization by Nicotine of Deficient Auditory Sensory Gating in the Relatives of Schizophrenics,”Biol. Psychiatry, 32(7): 607-616 (1992).
Afify, E.A., “Turnover of μ-opiod receptors in neuroblastoma cells,”Molecular Brain Research, 106: 83-87 (2002).
Albuquerque et al. “Sites of Action of Phencyclidine II. Interaction with the Ionic channel of the Nicotinic Receptor,”Molecular Pharmacology, (1980), 18: 167-178.
Arneric, S., et al., “Preclinical Pharmacology of ABT-418: A Prototypical Cholinergic Channel Activator for the Potential Treatment of Alzheimer's Disease,”CNS Drug Rev. 1(1): 1-26 (1995).
Arneric, S., et al., “Cholinergic channel modulators as a novel therapeutic strategy for Alzheimer's disease,”Exp. Opin. Invest. Drugs, 5(1): 79-100 (1996).
Asaoka, M., et al., “A New Synthetic Route to Functionalized 2-Azabicyclo[2.2.2]Octane,”Heterocycles, 38(11): 2455-2462 (1994).
Bannon, A.W., et al., “ABT-594[(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: A Novel, Orally Effective Antinociceptive Agent Acting via Neuronal Nicotinic Acetylcholine Receptors: II. In Vivo Characterization,”J. Pharmaco.l Exp. Ther., 285(2): 787-794 (1998).
Bannon, A.W., et al., “Broad-Spectrum, Non-Opioid Analgesic Activity by Selective Modulation of Neuronal Nicotinic Acetylcholine Receptors,”Science279: 77-81 (1998).
Baron, J.A., “Cigarette smoking and Parkinson's Disease,”Neurology, 36:1490-1496 (1986).
Bencherif, M., and J. D. Schmitt, “Targeting Neuronal Nicotinic Receptors: a Path to New Therapies,”Current Drug Targets, 1(4): 349-357 (2002).
Bencherif, M., et al., “RJR-2403: A Nicotinic Agonist with CNS Selectivity I: in Vitro Characterization,”J. Pharmacol. Exper. Therapeutics, 279(3): 1413-1421 (1996).
Bencherif M. and R.J. Lukas, “Differential Regulation of Nicotinic Acetylcholine Receptor Expression by Human TE671/RD Cells Following Second Messenger Modulation and Sodium Butyrate Treatments,”Mol Cell Neurosci.,2(1): 52-65 (1991).
Bencherif, M., and R.J. Lukas, “Ligand Binding and Functional Characterization of Muscarinic Acetylcholine Receptors on the TE671/RD Human Cell Line,”J. Pharmacol. Exp. Ther., 257(3): 946-953 (1991).
Bennett, G.J., and Y.-K. Xie, “A peripheral mononeuropathy in rat that produced disorders of pain sensation like those seen in man,”Pain, 33: 87-107 (1988).
Boger, D.L., et al., “Synthetic Analgesics: Preparation of Racemic 6,7-Benzomorphans,” Tet. Lett., 23(44): 4559-4562 (1982).
Bok, Th. R., and W.N. Speckamp, “Synthesis and Conformational Analysis of EXO-and ENDO-7-Substituted-3-Azabicyclo[3.3.1.]Nonanes,”Tetrahedron, 35: 267-272 (1979).
Bok, Th. R. and Speckamp, W.N., “3-Azanoradamantanes,”Heterocycles, 12(3): 343-347 (1979).
Brioni, J.D., et al., “The Pharmacology of (—)-Nicotine and Novel Cholinergic Channel Modulators,”Adv. Pharmacol., 37: 153-214 (1997).
Calderon-Gonzalez, R., and R.F. Calderon-Sepulveda, “Tourette Syndrome Current Concepts,”Intern. Pediat,, 8(2): 176-188 (1993).
Cheng, Yung-Chi, and W.H. Prusoff, “Relationship Between the Inhibition Constant (K1) and the Concentration of Inhibitor which Causes 50 Per Cent inhibition (I50) of an Enzymatic Reaction,”Biochem. Pharmacol., 22(23): 3099-3108 (1973).
Chiari, A., et al., “Sex Differences in Cholinergic Analgesia I: A Supplemental Nicotinic Mechanism in Normal Females,”Anesthesiology, 91(5): 1447-1454 (1999).
Clarke, P.B.S., et al., “Electrophysiological actions of nicotine on substantia nigra single units,”Br. J. Pharm., 85(4): 827-835 (1985).
D'amour, F.E., and D.L. Smith, “A Method for Determining Loss of Pain Sensation,”J. Pharmacol. Exp. Ther., 72: 74-79 (1941).
Damaj, M.I., et al., “The antinociceptive effects of α7 nicotinic agonists in an acute pain model,”Neuropharmacology, 39: 2785-2791 (2000).
Damaj, M.I., et al., “Antinociceptive and Pharmacological Effects of Metanicotine, a Selective Nicotinic Agonist,”J. Pharmacol. Exp. Ther. 291(1): 390-398 (1999).
Davies, A.R.L., et al., “Characterisation of the binding of [3H]methyllycaconitine: a new radioligand for labeling α7-type neuronal nicotinic acetylcholine receptors,”Neuropharmacol., 38: 679-690 (1999).
Decina, P., et al., “Cigarette Smoking and Neuroleptic-Induced Parkinsonism,”Biol. Psychiatry, 28(6): 502-508 (1990).
Devor, E.J., and Keith E. Isenberg, “Nicotine and Tourette's Syndrome,”The Lancet2(8670): 1046 (1989).
Dolle, F., et al., “Synthesis and preliminary evaluation of a carbon-11-labelled agonist of the α-7 nicotinic acetylcholine receptor,”J. Labelled Comp. Radiopharm., 44: 785-795 (2001).
Dwoskin, L.P., et al., “Recent developments in neuronal nicotinic acetylcholine receptor antagonists,”Exp. Opin. Ther. Patents, 10(10): 1561-1581 (2000).
Dwoskin, et al., “Discovery of a novel nicotinic receptor antagonist for the treatment of nicoti
Bhatti Balwinder Singh
Breining Scott R.
Hawkins Gregory D.
Mazurov Anatoly
Miao Lan
Desai Rita J
Fix Amy H.
O'Dell David K
Targacept, Inc.
Womble Carlyle Sandridge & Rice PLLC
LandOfFree
Pharmaceutical compositions and methods for relieving pain... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions and methods for relieving pain..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions and methods for relieving pain... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2763935